P81 What is the ideal target preterm population that might benefit from the expensive palivizumab prophylaxis?
IntroductionPalivizumab is a monoclonal antibody that reduces the likelihood of serious respiratory tract infection by Respiratory Syncytial Virus (RSV) in infants with Chronic Lung Disease (CLD) defined as an ongoing oxygen requirement at 36 weeks corrected gestation. In the UK (UK), Palivizumab is...
Gespeichert in:
| Veröffentlicht in: | Thorax 2017-12, Vol.72 (Suppl 3), p.A126 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | Suppl 3 |
| container_start_page | A126 |
| container_title | Thorax |
| container_volume | 72 |
| creator | Tsilika, L Batra, D Prayle, AP Hurley, M Bhatt, JM |
| description | IntroductionPalivizumab is a monoclonal antibody that reduces the likelihood of serious respiratory tract infection by Respiratory Syncytial Virus (RSV) in infants with Chronic Lung Disease (CLD) defined as an ongoing oxygen requirement at 36 weeks corrected gestation. In the UK (UK), Palivizumab is offered to high-risk infants with moderate to severe CLD according to their chronological age at the time of RSV season as per Joint Committee on Vaccination and Immunisation (JCVI) guidelines. The American Academy of Paediatrics, in contrast, recommends Palivizumab prophylaxis for all infants born before 29 weeks’ gestation who are younger than 12 months at the start of the RSV season.Materials and MethodsWe hypothesised that the RSV hospitalisation rate and length of hospital stay (LOS) within the 1 st year of life between preterm babies with CLD immunised according to the JCVI criteria (CLDJCVI) and the additional babies who are considered eligible by the AAP criteria would be comparable. Our cohort included babies born in Nottingham UK between 2009 and 2015. Data was collected from hospital records and the Nottingham CLD database, and analysed using Fisher’s exact test for proportions and Mann-Whitney test for continuous data.ResultsIn total there were 3478 babies born preterm ( |
| doi_str_mv | 10.1136/thoraxjnl-2017-210983.223 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_bmj_p</sourceid><recordid>TN_cdi_proquest_journals_1970925497</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1970925497</sourcerecordid><originalsourceid>FETCH-LOGICAL-b1243-81e67743f5735d774d654199d6b9af2c7eab3116387f3eec1a40a4ea0f92a63</originalsourceid><addsrcrecordid>eNo9kM1KxDAUhYMoOI6-Q8R1NTdJk2YlMvgHAwoKLkM6vZ2m9M82M8y4cuOL-iR2HHF17-I758BHyDmwSwChrkLR9m5TNlXEGeiIAzOJuORcHJAJSJVEght1SCaMSRYpodUxORmGkjGWAOgJ6Z4T-P78eitcoH6goUDqM3QVDa5fYqBdjwH7mnZtt6pc8G0zMiNb-2URaIoN5j7QvG_r3yxuOmwGv0baucqv_ceqdulY0nbFtnIbP1yfkqPcVQOe_d0pebm7fZ09RPOn-8fZzTxKgUsRJYBKaynyWIs4G79MxRKMyVRqXM4XGl0qAJRIdC4QF-AkcxIdyw13SkzJxb51nH5f4RBs2a76Zhy0YDQzPJZGj5TcU2ld2q73teu3FpjdmbX_Zu3OrN2btaNZ8QNwcHF0</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1970925497</pqid></control><display><type>article</type><title>P81 What is the ideal target preterm population that might benefit from the expensive palivizumab prophylaxis?</title><source>Alma/SFX Local Collection</source><creator>Tsilika, L ; Batra, D ; Prayle, AP ; Hurley, M ; Bhatt, JM</creator><creatorcontrib>Tsilika, L ; Batra, D ; Prayle, AP ; Hurley, M ; Bhatt, JM</creatorcontrib><description>IntroductionPalivizumab is a monoclonal antibody that reduces the likelihood of serious respiratory tract infection by Respiratory Syncytial Virus (RSV) in infants with Chronic Lung Disease (CLD) defined as an ongoing oxygen requirement at 36 weeks corrected gestation. In the UK (UK), Palivizumab is offered to high-risk infants with moderate to severe CLD according to their chronological age at the time of RSV season as per Joint Committee on Vaccination and Immunisation (JCVI) guidelines. The American Academy of Paediatrics, in contrast, recommends Palivizumab prophylaxis for all infants born before 29 weeks’ gestation who are younger than 12 months at the start of the RSV season.Materials and MethodsWe hypothesised that the RSV hospitalisation rate and length of hospital stay (LOS) within the 1 st year of life between preterm babies with CLD immunised according to the JCVI criteria (CLDJCVI) and the additional babies who are considered eligible by the AAP criteria would be comparable. Our cohort included babies born in Nottingham UK between 2009 and 2015. Data was collected from hospital records and the Nottingham CLD database, and analysed using Fisher’s exact test for proportions and Mann-Whitney test for continuous data.ResultsIn total there were 3478 babies born preterm (<37 weeks GA) in Nottingham UK from 2009 to 2015. 459 babies were born in Nottingham at <29 weeks GA. 245 babies had CLD at 36 weeks corrected GA and 135 of these babies were eligible for Palivizumab (JCVI).Abstract P81 Table 1The number of babies hospitalised and the average LOSNumber of babiesBabies immunised according to JCVI criteriaAdditional babies who would be eligible by AAP criteriap Value Total135160Confirmed RSV hospitalisations following discharge from neonatal unit within 1 st year of life 13 (9.6%) 13 (8.13%) 0.68Average LOS in days (IQR)10.3 days6.92 days0.5ConclusionThe RSV hospitalisation rate and LOS were not statistically different in babies under JCVI criteria and additional babies qualifying by AAP criteria. A larger multi-centre prospective study is required to prove health and economic benefits of adopting AAP Palivizumab recommendations.</description><identifier>ISSN: 0040-6376</identifier><identifier>EISSN: 1468-3296</identifier><identifier>DOI: 10.1136/thoraxjnl-2017-210983.223</identifier><language>eng</language><publisher>London: BMJ Publishing Group LTD</publisher><subject>Babies ; Immunotherapy ; Monoclonal antibodies ; Respiratory syncytial virus</subject><ispartof>Thorax, 2017-12, Vol.72 (Suppl 3), p.A126</ispartof><rights>2017, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</rights><rights>Copyright: 2017 © 2017, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids></links><search><creatorcontrib>Tsilika, L</creatorcontrib><creatorcontrib>Batra, D</creatorcontrib><creatorcontrib>Prayle, AP</creatorcontrib><creatorcontrib>Hurley, M</creatorcontrib><creatorcontrib>Bhatt, JM</creatorcontrib><title>P81 What is the ideal target preterm population that might benefit from the expensive palivizumab prophylaxis?</title><title>Thorax</title><description>IntroductionPalivizumab is a monoclonal antibody that reduces the likelihood of serious respiratory tract infection by Respiratory Syncytial Virus (RSV) in infants with Chronic Lung Disease (CLD) defined as an ongoing oxygen requirement at 36 weeks corrected gestation. In the UK (UK), Palivizumab is offered to high-risk infants with moderate to severe CLD according to their chronological age at the time of RSV season as per Joint Committee on Vaccination and Immunisation (JCVI) guidelines. The American Academy of Paediatrics, in contrast, recommends Palivizumab prophylaxis for all infants born before 29 weeks’ gestation who are younger than 12 months at the start of the RSV season.Materials and MethodsWe hypothesised that the RSV hospitalisation rate and length of hospital stay (LOS) within the 1 st year of life between preterm babies with CLD immunised according to the JCVI criteria (CLDJCVI) and the additional babies who are considered eligible by the AAP criteria would be comparable. Our cohort included babies born in Nottingham UK between 2009 and 2015. Data was collected from hospital records and the Nottingham CLD database, and analysed using Fisher’s exact test for proportions and Mann-Whitney test for continuous data.ResultsIn total there were 3478 babies born preterm (<37 weeks GA) in Nottingham UK from 2009 to 2015. 459 babies were born in Nottingham at <29 weeks GA. 245 babies had CLD at 36 weeks corrected GA and 135 of these babies were eligible for Palivizumab (JCVI).Abstract P81 Table 1The number of babies hospitalised and the average LOSNumber of babiesBabies immunised according to JCVI criteriaAdditional babies who would be eligible by AAP criteriap Value Total135160Confirmed RSV hospitalisations following discharge from neonatal unit within 1 st year of life 13 (9.6%) 13 (8.13%) 0.68Average LOS in days (IQR)10.3 days6.92 days0.5ConclusionThe RSV hospitalisation rate and LOS were not statistically different in babies under JCVI criteria and additional babies qualifying by AAP criteria. A larger multi-centre prospective study is required to prove health and economic benefits of adopting AAP Palivizumab recommendations.</description><subject>Babies</subject><subject>Immunotherapy</subject><subject>Monoclonal antibodies</subject><subject>Respiratory syncytial virus</subject><issn>0040-6376</issn><issn>1468-3296</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>BENPR</sourceid><recordid>eNo9kM1KxDAUhYMoOI6-Q8R1NTdJk2YlMvgHAwoKLkM6vZ2m9M82M8y4cuOL-iR2HHF17-I758BHyDmwSwChrkLR9m5TNlXEGeiIAzOJuORcHJAJSJVEght1SCaMSRYpodUxORmGkjGWAOgJ6Z4T-P78eitcoH6goUDqM3QVDa5fYqBdjwH7mnZtt6pc8G0zMiNb-2URaIoN5j7QvG_r3yxuOmwGv0baucqv_ceqdulY0nbFtnIbP1yfkqPcVQOe_d0pebm7fZ09RPOn-8fZzTxKgUsRJYBKaynyWIs4G79MxRKMyVRqXM4XGl0qAJRIdC4QF-AkcxIdyw13SkzJxb51nH5f4RBs2a76Zhy0YDQzPJZGj5TcU2ld2q73teu3FpjdmbX_Zu3OrN2btaNZ8QNwcHF0</recordid><startdate>201712</startdate><enddate>201712</enddate><creator>Tsilika, L</creator><creator>Batra, D</creator><creator>Prayle, AP</creator><creator>Hurley, M</creator><creator>Bhatt, JM</creator><general>BMJ Publishing Group LTD</general><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>201712</creationdate><title>P81 What is the ideal target preterm population that might benefit from the expensive palivizumab prophylaxis?</title><author>Tsilika, L ; Batra, D ; Prayle, AP ; Hurley, M ; Bhatt, JM</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b1243-81e67743f5735d774d654199d6b9af2c7eab3116387f3eec1a40a4ea0f92a63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Babies</topic><topic>Immunotherapy</topic><topic>Monoclonal antibodies</topic><topic>Respiratory syncytial virus</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tsilika, L</creatorcontrib><creatorcontrib>Batra, D</creatorcontrib><creatorcontrib>Prayle, AP</creatorcontrib><creatorcontrib>Hurley, M</creatorcontrib><creatorcontrib>Bhatt, JM</creatorcontrib><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>Thorax</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tsilika, L</au><au>Batra, D</au><au>Prayle, AP</au><au>Hurley, M</au><au>Bhatt, JM</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>P81 What is the ideal target preterm population that might benefit from the expensive palivizumab prophylaxis?</atitle><jtitle>Thorax</jtitle><date>2017-12</date><risdate>2017</risdate><volume>72</volume><issue>Suppl 3</issue><spage>A126</spage><pages>A126-</pages><issn>0040-6376</issn><eissn>1468-3296</eissn><abstract>IntroductionPalivizumab is a monoclonal antibody that reduces the likelihood of serious respiratory tract infection by Respiratory Syncytial Virus (RSV) in infants with Chronic Lung Disease (CLD) defined as an ongoing oxygen requirement at 36 weeks corrected gestation. In the UK (UK), Palivizumab is offered to high-risk infants with moderate to severe CLD according to their chronological age at the time of RSV season as per Joint Committee on Vaccination and Immunisation (JCVI) guidelines. The American Academy of Paediatrics, in contrast, recommends Palivizumab prophylaxis for all infants born before 29 weeks’ gestation who are younger than 12 months at the start of the RSV season.Materials and MethodsWe hypothesised that the RSV hospitalisation rate and length of hospital stay (LOS) within the 1 st year of life between preterm babies with CLD immunised according to the JCVI criteria (CLDJCVI) and the additional babies who are considered eligible by the AAP criteria would be comparable. Our cohort included babies born in Nottingham UK between 2009 and 2015. Data was collected from hospital records and the Nottingham CLD database, and analysed using Fisher’s exact test for proportions and Mann-Whitney test for continuous data.ResultsIn total there were 3478 babies born preterm (<37 weeks GA) in Nottingham UK from 2009 to 2015. 459 babies were born in Nottingham at <29 weeks GA. 245 babies had CLD at 36 weeks corrected GA and 135 of these babies were eligible for Palivizumab (JCVI).Abstract P81 Table 1The number of babies hospitalised and the average LOSNumber of babiesBabies immunised according to JCVI criteriaAdditional babies who would be eligible by AAP criteriap Value Total135160Confirmed RSV hospitalisations following discharge from neonatal unit within 1 st year of life 13 (9.6%) 13 (8.13%) 0.68Average LOS in days (IQR)10.3 days6.92 days0.5ConclusionThe RSV hospitalisation rate and LOS were not statistically different in babies under JCVI criteria and additional babies qualifying by AAP criteria. A larger multi-centre prospective study is required to prove health and economic benefits of adopting AAP Palivizumab recommendations.</abstract><cop>London</cop><pub>BMJ Publishing Group LTD</pub><doi>10.1136/thoraxjnl-2017-210983.223</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0040-6376 |
| ispartof | Thorax, 2017-12, Vol.72 (Suppl 3), p.A126 |
| issn | 0040-6376 1468-3296 |
| language | eng |
| recordid | cdi_proquest_journals_1970925497 |
| source | Alma/SFX Local Collection |
| subjects | Babies Immunotherapy Monoclonal antibodies Respiratory syncytial virus |
| title | P81 What is the ideal target preterm population that might benefit from the expensive palivizumab prophylaxis? |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T03%3A08%3A40IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_bmj_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=P81%E2%80%85What%20is%20the%20ideal%20target%20preterm%20population%20that%20might%20benefit%20from%20the%20expensive%20palivizumab%20prophylaxis?&rft.jtitle=Thorax&rft.au=Tsilika,%20L&rft.date=2017-12&rft.volume=72&rft.issue=Suppl%203&rft.spage=A126&rft.pages=A126-&rft.issn=0040-6376&rft.eissn=1468-3296&rft_id=info:doi/10.1136/thoraxjnl-2017-210983.223&rft_dat=%3Cproquest_bmj_p%3E1970925497%3C/proquest_bmj_p%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1970925497&rft_id=info:pmid/&rfr_iscdi=true |